

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.

**THIS PAGE BLANK (USPTO)**



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

10/023586  
10/023586  
10/023586



I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed


*Andrew Gersy*

Dated

30 August 2001

**THIS PAGE BLANK (USPTO)**

For official use



19DEC00 E592424-1 D01298  
P01/7700 0.00-0030855.1

Your reference  
PCS10960BXP-PROV

0030855.1

18 DEC 2000

#### Notes

Please type, or write in dark ink using CAPITAL letters. A prescribed fee is payable for a request for grant of a patent. For details, please contact the Patent Office (telephone 071-438 4700).

Rule 16 of the Patents Rules 1990 is the main rule governing the completion and filing of this form.

2 Do not give trading styles, for example, 'Trading as XYZ company', nationality or former names, for example, 'formerly (known as) ABC Ltd' as these are not required.

#### Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977 and will inform the applicant if such prohibition or restriction is necessary. Applicants resident in the United Kingdom are also reminded that under Section 23, applications may not be filed abroad without written permission unless an application has been filed not less than 6 weeks previously in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction revoked.

The  
Patent  
Office

## Request for grant of a Patent Form 1/77

Patents Act 1977

### 1 Title of invention

NOVEL POLYPEPTIDE

1 Please give the title of the invention

### 2 Applicant's details

☐ First or only applicant

2a If you are applying as a corporate body please give:

Corporate name  
PFIZER LIMITED

Country (and State of incorporation, if appropriate)

UNITED KINGDOM

2b If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

2c In all cases, please give the following details:

Address  
RAMSGATE ROAD  
SANDWICH  
KENT

UK postcode CT13 9NJ  
(if applicable)

Country UNITED KINGDOM

ADP number (if known) 6842673001

**2d, 2e and 2f:**

*If there are further applicants  
please provide details on a separate  
sheet of paper.*

☐ **Second applicant (if any)**

**2d** If you are applying as a corporate body please give:

Corporate name

Country (and State of incorporation, if appropriate)

**2e** If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

**2f** In all cases, please give the following details:

Address

UK postcode  
(if applicable)

Country

ADP number  
(if known)

**3**

*An address for service in the United  
Kingdom must be supplied.*

*Please mark correct box*

**3 Address for service details**

**3a** Have you appointed an agent to deal with your application?

Yes ☒ No ☐ ➡ go to 3b



*Please give details below*

Agent's name

DR. B. PETER

Agent's address

PFIZER LIMITED

RAMSGATE ROAD

SANDWICH

KENT

Postcode CT13 9NJ

Agent's ADP  
number 6892673001

**3b:**

*If you have appointed an agent,  
all correspondence concerning  
your application will be sent to  
the agent's United Kingdom  
address.*

**3b** If you have not appointed an agent please give a name and address in the United Kingdom to which all correspondence will be sent:

Name

Address

Postcode  
ADP number  
(if known)

Daytime telephone  
number (if available)

**4 Reference number**

4 Agent's or applicant's  
reference number  
(if applicable)

PCS10960BXP-PROV

**5 Claiming an earlier application date**

5 Are you claiming that this application be treated as having been filed on the date of filing of an earlier application?

Please mark correct box

Yes ☐ No ☒ **go to 6**

↓  
please give details below

☐ number of earlier  
application or patent  
number

☐ filing date  
(day month year)

☐ and the Section of the Patents Act 1977 under which you are claiming:

Please mark correct box

15(4) (Divisional) ☐ 8(3) ☐ 12(6) ☐ 37(4) ☐

**6**

If you are declaring priority from a  
PCT Application please enter 'PCT'  
as the country and enter the country  
code (for example, GB) as part of the  
application number.

Please give the date in all number  
format, for example, 31/05/90 for 31  
May 1990.

**6 Declaration of priority**

6 If you are declaring priority from previous application(s), please give:

Country of filing	Priority application number (if known)	Filing date (day, month, year)
-------------------	---	-----------------------------------

--	--	--

7

The answer must be 'No' if:  
 - any applicant is not an inventor  
 - there is an inventor who is not an applicant, or  
 - any applicant is a corporate body.

8

Please supply duplicates of claim(s), abstract, description and drawing(s).

Please mark correct box(es)

9

You or your appointed agent (see Rule 90 of the Patents Rules 1990) must sign this request.

Please sign here →

A completed fee sheet should preferably accompany the fee.

## 7 Inventorship

7 Are you (the applicant or applicants) the sole inventor or the joint inventors?

Please mark the correct box

Yes ☐ No ☒ →

A statement of Inventorship on Patents Form 7/77 will need to be filed (see Rule 15).

## 8 Checklist

8a Please fill in the number of sheets for each of the following types of document contained in this application.

Continuation sheets for this Patents Form 1/77

Claim(s)

Description

Abstract

Drawing(s)

8b Which of the following documents also accompanies the application?

Priority documents (please state how many)

Translation(s) of Priority document(s) (please state how many)

Patents Form 7/77 - Statement of Inventorship and Right to Grant (please state how many)

Patents Form 9/77 - Preliminary Examination/Search

Patents Form 10/77 - Request for Substantive Examination

## 9 Request

I/We request the grant of a patent on the basis of this application.

Signed Beake Peter Date 18/12/2000  
 (day month year)

Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to:

☐ The Comptroller  
 The Patent Office  
 Cardiff Road  
 NEWPORT  
 Gwent  
 NP9 1RH

The Comptroller  
 The Patent Office  
 25 Southampton Buildings  
 London  
 WC2A 1AY



## NOVEL POLYPEPTIDE

### Technical field

5

The present invention relates to a novel polynucleotide sequence which encodes a novel polypeptide belonging to the class of proteins known as G-protein coupled receptors (GPCRs). The present invention also relates, inter alia, to processes for producing the polypeptide and its uses.

10

### Background of the invention

Cells and tissues respond to a wide variety of extracellular signalling molecules through the interaction of these molecules with specific cell-surface receptors. One such class of receptors are known as G-protein coupled receptors (GPCRs) and these are characterised by containing a series of 7 hydrophobic transmembrane segments. Upon binding an extracellular ligand to its receptor, intracellular signals are initiated via interactions with heterotrimeric G proteins which in turn can lead to a number of different intracellular events depending upon which receptor has been activated. For example some GPCRs influence adenylyl cyclase activity whereas others act via phospholipase C.

Members of the GPCR superfamily respond to a wide variety of ligands including small molecule amines (such as serotonin, dopamine, acetylcholine), lipid-derived mediators (such as LpA), amino acid derivatives (such as glutamate) and neurotransmitter peptides and hormones (such as neurokinin, galanin, glucagon, gastrin). Although GPCRs are activated by a broad range of ligands, it should be noted that individual GPCRs have a small and very specific repertoire of ligands. Based upon an analysis of the primary structure of a novel GPCR, it is now possible to classify them into specific sub-families, thereby narrowing the range of potential ligands.

30

In many cases, the endogenous ligands of GPCRs are relatively small, enabling them to be mimicked or blocked by synthetic analogues. For example drugs such as prazosin,

doxazosin, cimetidine, ranitidine are all effective antagonists of their respective target GPCRs.

Thus, as the activation or inhibition of GPCRs can have therapeutic consequences, there is  
5 a continued need to provide new GPCRs and their associated agonists and antagonists.

### **Summary of the invention**

10 According to one aspect of the present invention, there is provided an isolated polynucleotide comprising:

- (a) a polynucleotide encoding the polypeptide as set forth in Figure 2;
- (b) a polynucleotide encoding the polypeptide expressed by the DNA  
15 contained in National Collection of Industrial and Marine Bacteria Limited (NCIMB) Deposit No. [REDACTED];
- (c) a polynucleotide comprising a nucleotide sequence of Figure 1;
- (d) a polynucleotide comprising a nucleotide sequence that has at least 70-75% identity to the polynucleotide of any one of (a) to (c);
- 20 (e) a polynucleotide comprising a nucleotide sequence which is capable of hybridising to the polynucleotide of any one of (a) to (d); or
- (f) a polynucleotide fragment of the polynucleotide of any one of (a) to (e).

Preferably, the polynucleotide comprises a nucleotide sequence that has at least 75-80%  
25 identity to the polynucleotide of any one of (a) to (c) above. More preferably, the polynucleotide comprises a nucleotide sequence that has at least 80-85% identity to the polynucleotide of any one of (a) to (c) above. Even more preferably, the polynucleotide comprises a nucleotide sequence that has at least 85-90% identity to the polynucleotide of any one of (a) to (c) above. Yet more preferably, the polynucleotide comprises a  
30 nucleotide sequence that has at least 90-95% identity to the polynucleotide of any one of (a) to (c) above. Most preferably, the polynucleotide comprises a nucleotide sequence that has greater than 95% identity to the polynucleotide of any one of (a) to (c) above.

Preferably, the polynucleotide encodes a mature polypeptide encoded by the DNA contained in NCIMB Deposit No.                     .

5 The polynucleotide described above preferably encodes a G-protein coupled receptor (GPCR).

The present invention also provides a polynucleotide probe or primer comprising at least 15 contiguous nucleotides of the polynucleotide described above.

10 The present invention yet further provides a vector comprising the polynucleotide described above.

According to a further aspect of the present invention, there is provided a host cell transformed or transfected with the vector described above. Preferably, the host cell is a  
15 mammalian, bacterial or yeast cell.

According to yet a further aspect of the present invention, there is provided a process for producing a polypeptide or fragment thereof comprising culturing said host cell under conditions sufficient for the expression of said polypeptide or fragment. Preferably, said  
20 polypeptide or fragment is expressed at the surface of said cell. The process preferably further includes recovering the polypeptide or fragment from the culture.

There is also provided by the present invention a process for producing cells capable of expressing a polypeptide or fragment thereof comprising transforming or transfecting  
25 cells with the vector described above.

According to a further embodiment of the present invention, there are provided cells produced by the process described above. There is also provided a membrane preparation of said cells.

30

According to another aspect of the present invention, there is provided a polypeptide comprising:

- (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in Figure 1 and variants, fragments, homologues, analogues and derivatives thereof;
- (b) a polypeptide of Figure 2 and variants, fragments, homologues, analogues and derivatives thereof; or
- (c) a polypeptide encoded by the cDNA of NCIMB Deposit No. 144333 and variants, fragments, homologues, analogues and derivatives of said polypeptide.
- 10 There is also provided by the present invention an antibody against the polypeptide described above.

The present invention yet further provides a compound which activates the polypeptide described above (an agonist) or which inhibits activation of the polypeptide described above (an antagonist).

According to another aspect of the present invention, there is provided a method for identifying a compound which binds to and activates the polypeptide described above comprising:

- (a) contacting a compound with cells expressing on the surface thereof the polypeptide or a membrane preparation of said cells, said polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said polypeptide; said contacting being under conditions sufficient to permit binding of compounds to the polypeptide; and
- (b) identifying a compound capable of polypeptide binding by detecting the signal produced by said second component.

According to another aspect of the present invention, there is provided a method for identifying a compound which binds to and inhibits activation of the polypeptide described above comprising:

(a) contacting (i) a detectable first component known to bind to and activate the polypeptide and (ii) a compound with cells expressing on the surface thereof the polypeptide or a membrane preparation of said cells, said polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said polypeptide; said contacting being under conditions sufficient to permit binding of compounds to the polypeptide; and

(b) determining whether the first component binds to the polypeptide by detecting the absence or otherwise of a signal generated from the interaction of the first component with the polypeptide.

As GPCRs are involved in signal transduction, agonists or antagonists of the polypeptide of the present invention can find use in interfering in the signal transduction process. Consequently, the present invention provides a compound which activates the polypeptide described above (an agonist) or which inhibits activation of the polypeptide described above (an antagonist) for use as a pharmaceutical. Such compounds, which can act as agonists or antagonists of the polypeptide, can therefore find use in the therapeutic areas which concern aspects of signal transduction. Therapeutically usefully areas include, but are not limited to, neurological disease, psychotherapeutics, urogenital disease, reproduction and sexual medicine, inflammation, cancer, tissue repair, dermatology, skin pigmentation, photoageing, frailty, osteoporosis, metabolic disease, cardiovascular disease, gastrointestinal disease, antiinfection, allergy and respiratory disease, sensory organ disorders, sleep disorders and hairloss.

Accordingly, there is also provided the use of the above compound (agonist) in the manufacture of a medicament in the treatment of a patient having need to activate a receptor.

There is also provided the use of the above compound (antagonist) in the manufacture of a medicament in the treatment of a patient having need to inhibit a receptor.

According to yet a further aspect of the invention, there is provided a method for the treatment of a patient having need to activate a receptor comprising administering to the

patient a therapeutically effective amount of the above-described compound (agonist). Preferably, said compound (agonist) is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient DNA encoding said compound and expressing said compound in vivo.

5

According to yet a further aspect of the invention, there is also provided a method for the treatment of a patient having need to inhibit a receptor comprising administering to the patient a therapeutically effective amount of the above-described compound (antagonist). Preferably, said compound (antagonist) is a polypeptide and a therapeutically effective

10 amount of the compound is administered by providing to the patient DNA encoding said compound and expressing said compound in vivo.

15

There is also provided by the present invention a method for the treatment of a patient having need to activate or inhibit a receptor, comprising administering to the patient a therapeutically effective amount of the antibody described above.

20

Yet further provided by the present invention is use of the antibody described above in the manufacture of a medicament for the treatment of a patient having need to activate or inhibit a receptor.

25

According to a further aspect of the present invention, there is provided a method of treatment of a patient having need to upregulate a receptor, comprising administering to the patient a therapeutically effective amount of the polypeptide of the present invention. Preferably, said therapeutically effective amount of the polypeptide is administered by

25 providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.

30

There is also provided by the present invention, use of the polypeptide in the manufacture of a medicament for the treatment of a patient having need to upregulate a receptor.

According to yet a further aspect of the present invention, there are provided cells or an animal genetically engineered to overexpress, underexpress or to exhibit targeted deletion of the polypeptide of the present invention.

**Detailed description of the invention**

The present invention will now be described, by way of example only, with reference to  
5 the accompanying figures, wherein:

**Figure 1** shows the nucleotide sequence coding for PFI-020. The ATG translation initiation codon is indicated by the first three letters. The stop codon is indicated by the last three letters.

10

**Figure 2** shows the corresponding amino acid sequence coding for PFI-020.

**Figure 3** shows a ClustalW Alignment of PFI-020 with the P2U purinoceptor 1 (P2U1).

15 **Figure 4** shows the results of a functional, cell-based assay, showing the activation of PFI-020 by various nucleotide analogues, using a FLIPR® technology. Each square contains the fluorescence trace measured in the well of a 96-well plate in the corresponding position.

20 **Figure 5** shows the results of a functional, cell-based assay, showing the activation of PFI-020 by uridine triphosphate, using a FLIPR® technology. Each square contains the fluorescence trace measured in the well of a 96-well plate in the corresponding position.

25 The polynucleotide which encodes the GPCR of the present invention was identified electronically and analysed using various bioinformatic tools. The GPCR encoded by the sequences described herein has been termed PFI-020.

The term "nucleotide sequence" as used herein refers to an oligonucleotide sequence or  
30 polynucleotide sequence, and variants, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be DNA or RNA of genomic or synthetic or recombinant origin which may be double-stranded or single-stranded whether representing the sense or antisense strand.

Preferably, the term "nucleotide sequence" means DNA.

More preferably, the term "nucleotide sequence" means DNA prepared by use of  
5 recombinant DNA techniques (i.e. recombinant DNA).

In a preferred embodiment, the present invention does not cover the native nucleotide coding sequence according to the present invention in its natural environment when it is under the control of its native promoter which is also in its natural environment. For ease  
10 of reference, we shall call this preferred embodiment the "non-native nucleotide sequence".

As used herein "amino acid sequence" refers to peptide or protein sequences or portions thereof.  
15

In a preferred embodiment, the present invention does not cover the native PFI-020 according to the present invention when it is in its natural environment and when it has been expressed by its native nucleotide coding sequence which is also in its natural environment and when that nucleotide sequence is under the control of its native promoter  
20 which is also in its natural environment. For ease of reference, we shall call this preferred embodiment the "non-native amino acid sequence".

As used herein "naturally occurring" refers to a PFI-020 with an amino acid sequence found in nature.  
25

As used herein "biologically active" refers to a PFI-020 having structural, regulatory or biochemical functions of the naturally occurring PFI-020.

As used herein, "immunological activity" is defined as the capability of the natural,  
30 recombinant or synthetic PFI-020 or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The term "derivative" as used herein includes chemical modification of a PFI-020.



As used herein, the terms "isolated" and "purified" refer to molecules, either nucleic or amino acid sequences, that are removed from their natural environment and isolated or separated from at least one other component with which they are naturally associated. For  
5 example, for nucleic acid sequences, the nucleic acid must be separated from at least one of the genes with which it is naturally associated.

The terms "variant", "homologue" or "fragment" in relation to the amino acid sequence for the preferred polypeptide of the present invention include any substitution of, variation  
10 of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant polypeptide has PFI-020 activity. In particular, the term "homologue" covers homology with respect to structure and/or function.

15 The terms "variant", "homologue" or "fragment" in relation to the nucleotide sequence coding for the preferred polypeptide of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence codes for  
or is capable of coding for a polypeptide having PFI-020 activity. In particular, the term  
20 "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence codes for or is capable of coding for an enzyme having PFI-020 activity. With respect to sequence homology (i.e. identity), preferably there is at least 70-75%, more preferably at least 75-80%, more preferably at least 80-85%, more preferably 85-90%, yet more preferably 90-95%, and most preferably greater than 95%  
25 identity to the polynucleotide sequence shown in Figure 1.

In particular, the term "homology" as used herein may be equated with the term "identity". Relative sequence homology (i.e. sequence identity) can be determined by commercially available computer programs that can calculate % homology between two  
30 or more sequences. A typical example of such a computer program is CLUSTAL.

As used herein, the terms "variant", "homologue", "fragment" and "derivative" also include allelic variations of the sequences.

The term "variant" also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences presented herein. Preferably, the term "variant" encompasses sequences that are complementary to sequences that are capable of hybridising under stringent conditions (e.g. 65°C and 0.1xSSC {1xSSC = 0.15 M NaCl, 0.015 M Na<sub>3</sub> citrate pH 7.0}) to the nucleotide sequences presented herein.

The present invention also covers nucleotide sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein). In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention under stringent conditions (e.g. 65°C and 0.1xSSC).

The term "vector" includes expression vectors and transformation vectors.

The term "expression vector" means a construct capable of in vivo or in vitro expression.

The term "transformation vector" means a construct capable of being transferred from one species to another.

**The identification of PFI-020**

PFI-020 was identified in the Celera nucleotide database by searching the sequences with  
 5 known members of the G-protein coupled receptor (GPCR) family using the BLAST  
 algorithm. In order to confirm that PFI-020 was a member of the GPCR family, a number  
 of bioinformatics approaches were performed.

**(a) BLAST Search against Swissprot**

10

PFI-020 was searched against Swissprot using the BLAST algorithm (Basic Local  
 Alignment Search Tool (Altschul SF (1993) J.Mol. Evol. 36:290-300; Altschul, SF et al  
 (1990) J. Mol. Biol. 215:403-410) to identify the closest protein match. In this case the  
 top hit was to:

15

P41231, P2U purinoceptor 1 (P2U1) .

These results indicate that PFI-020 is a member of the GPCR family.

**20 (b) ClustalW Alignment of PFI-020 with the P2U purinoceptor 1 (P2U1).**

These results are shown in Figure 3.

**(c) BLAST search against a non-redundant human GPCR database**

25

PFI-020 was searched against a non-redundant human GPCR database comprising mainly  
 sequences from Genbank and the Derwent Geneseq databases in order to identify the class  
 of potential agonists for this receptor. The top ten hits are shown below:

30	P2U purinoceptor 1 (P2U1) [L:377]	235	5e-63
	Uridine nucleotide receptor (UNR) [L:...]	228	8e-61
	P2Y purinoceptor 6 (P2Y6) [L:328]	204	1e-53
	P2Y purinoceptor 1 (P2Y1) [L:373]	179	5e-46
	Purinoceptor homologue 6575963CD1 (incyte...)	150	3e-37
35	G protein-coupled receptor GPR17 [L:339]	147	2e-36
	P2Y purinoceptor 5 (P2Y5) [L:344]	139	3e-34
	P2Y purinoceptor 9 (P2Y9) [L:370]	139	6e-34

Proteinase activated receptor 3 (PAR-3...	130	2e-31
Cysteinyl leukotriene receptor (CYSLT1) ...	125	1e-29

(e value = statistical likelihood of the hit occurring by chance)

5

These results demonstrate that PFI-020 is most similar to purinergic receptors, and they suggest that PFI-020 encodes a novel GPCR whose ligand is likely to be a nucleotide or nucleotide derivative.

10 It will be appreciated that the foregoing is provided by way of example only and modification of detail may be made without departing from the scope of the invention.

### Example 3

#### 15 ISOLATION OF PFI-020

Utilising PFI-020 gene specific primers (PFI-020 forward and PFI-020 reverse; SEQ ID NOs: 3 and 4, respectively) these were employed in a PCR to amplify the PFI-020 coding region from human genomic DNA (Boehringer Mannheim), where the conditions were as follows:-

20

#### **PCR mix:**

PFI-020 primers	1 µl (10 µM stock)
25 Human genomic DNA	2 µl (400ng)
dNTPs (concentration as per kit)	1 µl
platinum Taq high fidelity Polymerase (LTI, Inc.)	0.5 µl
10x amplification Buffer (from PCR kit)	5 µl
MgSO <sub>4</sub>	1.5 µl
30 dH <sub>2</sub> O	39 µl

#### **PCR primers:**

Forward Primer (= PFI-020 forward):

5'- ACC ATG CTG TCC ATT TTG CTT CCT TCC-3' (SEQ ID NO: 3)

Reverse Primer (= PFI-020 reverse):

5'- TCA GTT TCT GGA GGA GCC TGA CTC-3' (SEQ ID NO: 4)

5

**PCR cycle:**

(1) 94°C 2 mins

(2) 94°C 30 seconds

(3) 54°C 30 seconds

10 (4) 68°C 2 mins

Steps (2) through to (4) were repeated for a further 27 cycles.

(5) 68°C 15 mins

(6) 4°C soak.

15 The PFI-020 PCR product was TOPO cloned (Invitrogen TOPO cloning methodology) into the vector pcDNA4.1/His-Max-TOPO (Invitrogen), according to the manufacturer's instructions. The resulting insert was subsequently sequence-verified on both strands using ABI DNA sequencing methodology as per the manufacturer's protocol.

20 **Example 4**

TISSUE DISTRIBUTION OF PFI-020

Electronic northern identifies an EST in a brain cDNA library.

25

**Example 5**

FUNCTIONAL CELL-BASED ASSAYS FOR AGONIST ACTIVATION OF PFI-020

30 Fluorescence Imaging Plate Reader (FLIPR®) technology was employed as a means to detect activation of PFI-020 by agonists in a cell-based assay.

5 x 10<sup>6</sup> Human Embryonic Kidney (HEK) 293 cells expressing the mouse Gα15 gene (from here on called '293 cells'), were transiently transfected with 7.5 µg of PFI-020 (contained within the pcDNA4HIS-max-TOPO (Invitrogen) plasmid) vector, or vector alone, using Lipofectamine Plus® reagent (Gibco BRL) as per the manufacturer's protocol. The plasmid pcDNA4HIS-max-TOPO was used as it contains elements that up-regulate the level of gene transcription over standard pcDNA3.1 vectors. 24 hrs post-transfection, the cells were detached from the flask using Trypsin/EDTA solution (LTI) and seeded into a black sided, poly-D-lysine-treated, 96-well plate (Becton Dickinson) at 5 x 10<sup>4</sup> cells/well density. The plates were left overnight to allow the cells to adhere to the bottom of the wells. The medium was removed from the cells and replaced with 100 µl warm (37°C) dye loading solution (50 µg Fluo3 (Molecular Probes) in 20 µl DMSO + 20% pluronic acid in DMSO, added to 11 ml Dulbecco's Modified Eagles Medium containing 1x Probenecid (100x Probenecid - 0.71 g Probenecid was dissolved in 5 ml 1M NaOH and 5 ml Dulbeccos' Phosphate Buffered Saline (PBS), per plate; Probenecid (Molecular Probes) inhibits activity of the anion transport protein, thus improving dye loading). The plates were then incubated for 1 hr at 37°C. Plates were subsequently washed with 250 µl of wash buffer per well (5 ml 100x Probenecid stock + 495 ml PBS, pH 7.4) 4 times. The plates were returned to the 37°C/5%CO<sub>2</sub> incubator for 30 mins prior to processing within the FLIPR® instrument. The FLIPR® processing involved reading the fluorescence for all samples for 2 minutes; during this time the fluorescence baseline was determined for the first 10 seconds. The desired amount of compound was then automatically transferred to the wells and the fluorescence was continuously monitored for the remainder of the time. All compounds were diluted in wash buffer

## **25 Analysis of PFI-020 activation by various purinoceptor agonist compounds in a FLIPR® cell-based assay**

Using methodology as described in detail above, purinoceptor agonist compounds were identified as being able to functionally activate PFI-020.

30

Figures 4 and 5 depict the action of various purinoceptor compounds at a concentration of 10 µM on PFI-020-transfected 293 cells. All compounds were purchased from Sigma. Vector-only transfected 293 cells gave no measurable response to these compounds. The

results indicate that PFI-020 is activated, by 2-chloroadenosine triphosphate tetrasodium (position F5 in Figure 4), 2-methylthioadenosine diphosphate trisodium (position F8 in Figure 4); 2-methylthioadenosine triphosphate tetrasodium (position G3, Figure 4) and Uridine triphosphate (position H10, Figure 5). All other responses are due to  
5 endogenously expressed receptors as these compounds illicit measurable responses in vector-only transfected 293 cells.

**Claims**

1. An isolated polynucleotide comprising:
  - 5 (a) a polynucleotide encoding the polypeptide as set forth in Figure 2;
  - (b) a polynucleotide encoding the polypeptide expressed by the DNA contained in National Collection of Industrial and Marine Bacteria Limited (NCIMB) Deposit No. \_\_\_\_\_;
  - 10 (c) a polynucleotide comprising a nucleotide sequence of Figure 1;
  - (d) a polynucleotide comprising a nucleotide sequence that has at least 70-75% identity to the polynucleotide of any one of (a) to (c);
  - (e) a polynucleotide comprising a nucleotide sequence which is capable of hybridising to the polynucleotide of any one of (a) to (d); or
  - 15 (f) a polynucleotide fragment of the polynucleotide of any one of (a) to (e).
2. The polynucleotide of claim 1, comprising a nucleotide sequence that has at least 75-80% identity to the polynucleotide of any one of (a) to (c).
- 20 3. The polynucleotide of claim 1, comprising a nucleotide sequence that has at least 80-85% identity to the polynucleotide of any one of (a) to (c).
4. The polynucleotide of claim 1, comprising a nucleotide sequence that has at least 85-90% identity to the polynucleotide of any one of (a) to (c).
- 25 5. The polynucleotide of claim 1, comprising a nucleotide sequence that has at least 90-95% identity to the polynucleotide of any one of (a) to (c).
6. The polynucleotide of claim 1, comprising a nucleotide sequence that has greater than  
30 95% identity to the polynucleotide of any one of (a) to (c).
7. The polynucleotide of claim 1, wherein said polynucleotide encodes a mature polypeptide encoded by the DNA contained in NCIMB Deposit No. \_\_\_\_\_.



8. The polynucleotide of any one of the preceding claims which encodes a G-protein coupled receptor (GPCR).
9. A polynucleotide probe or primer comprising at least 15 contiguous nucleotides of  
5 the polynucleotide of any one of the preceding claims.
10. A vector comprising the polynucleotide of any one of the preceding claims.
11. A host cell transformed or transfected with the vector of claim 10.
- 10 12. The host cell of claim 11 which is a mammalian, bacterial or yeast cell.
13. A process for producing a polypeptide or fragment thereof comprising culturing the host cell of claim 11 or claim 12 under conditions sufficient for the expression of said  
15 polypeptide or fragment.
14. The process of claim 13, wherein said polypeptide or fragment is expressed at the surface of said cell.
- 20 15. The process of claim 13 or claim 14 which further includes recovering the polypeptide or fragment from the culture.
16. A process for producing cells capable of expressing a polypeptide or fragment thereof comprising transforming or transfecting cells with the vector of claim 10.
- 25 17. Cells produced by the process of claim 14.
18. A membrane preparation of the cells of claim 17.
- 30 19. A polypeptide comprising:  
  
(a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in Figure 1 and variants, fragments, homologues, analogues and derivatives thereof;

(b) a polypeptide of Figure 2 and variants, fragments, homologues, analogues and derivatives thereof; or

(c) a polypeptide encoded by the cDNA of NCIMB Deposit No. 39520 and variants, fragments, homologues, analogues and derivatives of said polypeptide.

5

20. An antibody against the polypeptide of claim 19.

21. A compound (agonist) which activates the polypeptide of claim 19.

10 22. A compound (antagonist) which inhibits activation of the polypeptide of claim 19.

23. A method for identifying a compound which binds to and activates the polypeptide of claim 19 comprising:

15 (a) contacting a compound with cells expressing on the surface thereof the polypeptide of claim 19 or a membrane preparation of said cells, said polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said polypeptide; said contacting being under conditions sufficient to permit binding of compounds to the polypeptide; and

20

(b) identifying a compound capable of polypeptide binding by detecting the signal produced by said second component.

24. A method for identifying a compound which binds to and inhibits activation of the  
25 polypeptide of claim 19 comprising:

(a) contacting (i) a detectable first component known to bind to and activate the polypeptide of claim 19 and (ii) a compound with cells expressing on the surface thereof the polypeptide of claim 19, or a membrane preparation of said cells, said polypeptide  
30 being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said polypeptide; said contacting being under conditions sufficient to permit binding of compounds to the polypeptide; and

(b) determining whether the first component binds to the polypeptide by detecting the absence or otherwise of a signal generated from the interaction of the first component with the polypeptide.

5 25. The compound of claim 21 or claim 22 for use as a pharmaceutical.

26. Use of the compound (agonist) of claim 21 in the manufacture of a medicament in the treatment of a patient having need to activate a receptor.

10 27. Use of the compound (antagonist) of claim 22 in the manufacture of a medicament in the treatment of a patient having need to inhibit a receptor.

28. A method for the treatment of a patient having need to activate a receptor comprising administering to the patient a therapeutically effective amount of the compound of claim  
15 21.

29. The method of claim 28, wherein said compound is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient DNA encoding said compound and expressing said compound in vivo.

20

30. A method for the treatment of a patient having need to inhibit a receptor comprising administering to the patient a therapeutically effective amount of the compound of claim 22.

25 31. The method of claim 30, wherein said compound is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient DNA encoding said compound and expressing said compound in vivo.

32. A method for the treatment of a patient having need to activate or inhibit a receptor,  
30 comprising administering to the patient a therapeutically effective amount of the antibody of claim 20.

33. Use of the antibody of claim 20 in the manufacture of a medicament for the treatment of a patient having need to activate or inhibit a receptor.

34. A method of treatment of a patient having need to upregulate a receptor, comprising administering to the patient a therapeutically effective amount of the polypeptide of claim 19.

5

35. The method of claim 34, wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.

10 36. Use of the polypeptide of claim 19 in the manufacture of a medicament for the treatment of a patient having need to upregulate a receptor.

37. Cells or animals genetically engineered to overexpress the polypeptide of claim 19.

15 38. Cells or animals genetically engineered to underexpress the polypeptide of claim 19.

39. Cells or animals genetically engineered to exhibit targeted deletion of the polypeptide of claim 19.

Figure 1

5

Nucleotide sequence coding for PFI-020

atgctgtccatTTTgcttccttccaggggaagcagaagcgggagccgtcgtggagctct  
gctcctggaggaggagcctcccgggacatggagaaggtggacatgaatacatcacaggaac  
aaggtctctgccagttctcagagaagtacaagcaagtctacctctccctggcctacagt  
atcatctttatcctagggctgccactaaatggcactgtcttgtggcactcctggggcca  
10 aaccaagcgtggagctgtgccaccacctatctggtgaacctgatggtggccgacctgc  
tttatgtgctattgcccttcctcatcatcacctactcactagatgacaggtggcccttc  
ggggagctgctctgcaagctggtgcacttcctgttctatatcaacctttacggcagcat  
cctgctgctgacctgcatctctgtgcaccagttcctaggtgtgtggcaccactgtgtt  
cgctgccctaccggacccgcaggcatgcctggctgggcaccagcaccacctgggacctg  
15 gtggtcctccagctgctgcccacactggccttctcccacacggactacatcaatggcca  
gatgatctgggtatgacatgaccagccaagagaattttgatcggctttttgcctacggca  
tagttctgacattgtctggctttctttccccctccttgggtcattttggtgtgctattca  
ctgatggtcaggagcctgatcaagccagaggagaacctcatgaggacaggcaacacagc  
ccgagccaggtccatccggaccatcctactggtgtgtggcctcttcacctctgttttg  
20 tgcccttccatatcactcgtccttctacctcaccatctgctttctgctttctcaggac  
tgccagctcttgatggcaccacagtggtggcctacaagatatggaggcctctggtgagtg  
gagcagctgcctcaaccagtcctgtactttctttcaaggggggcaaaaatagagtcag  
gctcctccagaaactga

25

30

35

40

THIS PAGE BLANK (USPTO)

**Figure 2**

5

Amino acid sequence coding for PFI-020

MLSILLPSRGSRSRSGSRRGALLLEGASRDMEKVDMMNTSQQGLCQFSEKYKQVYLSLAYSI  
 IFILGLPLNGTVLWHSWGQTKRWSCATTYLVNLMVADLLYVLLPFLIITYSLDDRWPFG  
 10 LLCKLVHFLFYINLYGSILLITCISVHQFLGVWHPLCSLPYRTRRHAWLGTSTTWALVVL  
 QLLPTLAFSHTDYINGQMIWYDMMTSQENFDRLFAYGIVLTLSGFLSPSLVILVCYSLMVR  
 SLIKPEENLMRTGNTARARSIRTILLVCGFLTLCFVFPFHITRSFYLTICFLLSQDCQLLM  
 APSVAYKIWRPLVSVSSCLNPVLYFLSRGAKIESGSSRN

15

20

25

30

35

THIS PAGE BLANK (USPTO)



Figure 3

5

ClustalW Alignment of PFI-020 with P2U purinoceptor 1 (P2U1)

```

10  P2U1      MAADLGPNWNTINGTWDGD---ELGYR-----CRFNEDFKYVLLPVSYGV
    PFI-020  MLSILLPSRSGSRSGSRRGALLLEGASRDMKVDMMNTSQEQGLCQFSEKYKQVYLSLAYSI
          * : * * . . : . : * * . * * * * * . : * * . : * * . : * * . :
          * : * * . . : . : * * . * * * * * . : * * . : * * . : * * . :

15  P2U1      VCVLGLCLNAVALYIFLCRLKTWNASTTYMFHLAVSDALYAASLPLLVIYVYARGDHWPF
    PFI-020  IFILGLPLNGTVLWHSWGQTKRWSCATTYLVNLMVADLLYVL-LPFLIITYSLDDRWPFG
          : : * * * * * . : : * * . : * * . : * * . : * * . : * * . :
          : : * * * * * . : : * * . : * * . : * * . : * * . : * * . :

20  P2U1      TVLCKLVRFLEYTNLYCSILFLTCISVHRCLGVLRPLRLRWGRARYARRVAGAVVWLVL
    PFI-020  ELLCKLVHFLFYINLYGSILLTLCISVHQFLGVVHPLCSLPYRTRRHAWLGTSTTWALVV
          : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * :
          : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * :

25  P2U1      ACQAPVLYFVTTSARGGRVTCHDTSAPELFSRFVAYSSVMLGLLFAVPPFAVILVCYVLM
    PFI-020  LQLLPTLAFSHTDYINGQMIWYDMSQENFDRLFAYGIVLTLSGFLSPSLVILVCYSLMV
          * . * * * . . : : * * . : * * . : * * . : * * . : * * . :
          * . * * * . . : : * * . : * * . : * * . : * * . : * * . :

30  P2U1      RRLKLP--AYGTSGGLEPRAKRKSVRTIAVVLAVFALCFLPFHVTRTLYYSFRSLD-LSCH
    PFI-020  RSLIKPEENLMRTGNTARA-R-SIRTILLVCGLFTLCFVPFHITRSFYLTICFLLSQDCQ
          * * : * * . : * * . : * * . : * * . : * * . : * * . :
          * * : * * . : * * . : * * . : * * . : * * . : * * . :


35  P2U1      TLNAINMAYKVTRPLASANSCLDPVLYFLAGQLVRFARDAKPPTGSPATPARRRLGLR
    PFI-020  LLMAPSVAYKIWRPLVSVSSCLNPVLYFLS-----RGAKIESGSSRN-----
          * * . : * * . : * * . : * * . : * * . : * * . :
          * * . : * * . : * * . : * * . : * * . : * * . :

P2U1      RSDRTDMQRIGDVLGSSSEDFRRTSTPAGSENTKDIRL
PFI-020

```

THIS PAGE BLANK (USPL)

**Figure 4**




Range = ( -1000, 1000 )

**Mini Graphs**

THIS PAGE BLANK (COPY)

Figure 5



Range = ( -1000, 1000 )

Mini Graphs

THIS PAGE BLANK